[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bowel-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bowel-dysfunction":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,84,108,133,159,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100540310","seattle-spatial-transcriptomic-research-in-inflammatory-bowel-disease-evaluation-stride-100540310",false,"NCT06315179","Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)","Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation","STRIDE","Inclusion Criteria:\n\n* Suspected diagnosis of CD (Crohn's Disease), UC (Ulcerative Colitis) or Indeterminate colitis (IC)\n\nExclusion Criteria:\n\n* Evidence of Other Complicating Medical Issues:\n* Other serious medical conditions, such as neurological, liver, kidney, or systemic disease\n* Pregnancy\n* Tobacco, alcohol, or illicit drug abuse","ALL","6 Years","21 Years",{"count":21,"type":22},200,"ESTIMATED","3 Years","OBSERVATIONAL","This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation.",[27,28,29,30,31,32,33,34,35,36,37,38],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis","Indeterminate Colitis","Functional Abdominal Pain Syndrome","Functional Bowel Disorder","Esophageal Diseases","Gastroduodenal Disorder","Bowel Dysfunction","Gallbladder Diseases","Sphincter of Oddi Dysfunction","Anorectal Disorder",[40,41],"IBD","DGBI","RECRUITING","2026-04-21",{"date":45,"type":46},"2026-04-24","ACTUAL",{"date":48,"type":46},"2024-05-10",{"date":50,"type":22},"2030-01",{"name":52,"class":53},"Seattle Children's Hospital","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":54},"100561259","noninvasive-spinal-cord-stimulation-for-early-sci-100561259","NCT06587841","Noninvasive Spinal Cord Stimulation for Early SCI","Noninvasive Spinal Cord Neuromodulation to Improve Lower Urinary Tract Function After Spinal Cord Injury in Ukrainian War Veterans","Inclusion Criteria:\n\n* A participant must meet all of the following criteria in order to be eligible to participate:\n\n  1. Be a resident of either British Columbia (for Vancouver Site) with an active provincial medical service plan or Ukraine (for Ukraine Site) Age between 19 and 65 years at the time of consent\n  2. Subacute (time since injury 3-6 months) or chronic (time since injury 12+ months) SCI\n  3. ASIA Impairment Scale (AIS) A or B at spinal segments C5-T10\n  4. Documented impaired LUT function\n  5. Women of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:\n\n     i. Women of childbearing potential must have a confirmed negative pregnancy test prior to the baseline visit.\n\n     ii. Women of childbearing potential must agree to use adequate contraception during the period of the trial and for at least 28 days after completion of treatment. Effective contraception includes abstinence.\n  6. Sexually active males with female partners of childbearing potential must agree to use effective contraception during the period of the trial and for at least 28 days after completion of treatment.\n  7. Must provide informed consent.\n  8. Agrees to comply with all planned visits and assessments, adhere with established bowel and LUT routines and refrain from initiation of new medications for bowel and LUT management without notifying the Principal Investigator of this study.\n\n     Exclusion Criteria:\n* A participant who meets any of the following criteria will be ineligible to participate:\n\n  1. Clinically significant depression with thoughts of suicidal ideation (PHQ-9 total score above 20) or debilitating PTSD (PCL-5 total score above) or as judged by the investigator.\n  2. History of bladder augmentation or continent or incontinent urinary stoma or prior bladder surgery.\n  3. Exhibits signs of lower motor neuron injury (i.e., concomitant conus medullaris\u002Fcauda equina injury).\n  4. History of intradetrusor or intrasphincter onabotulinumtoxinA injections within 9 months of baseline visit.\n  5. Concurrent use of any medication or treatment that in the opinion of the investigator interferes with study outcomes.\n  6. Presence of cognitive impairments, social\u002Fpsychological problems, or other comorbid conditions that, in the opinion of the Investigator, will preclude them from participation and completion of the study\n  7. Presence of severe acute medical issues that interfere with testing (e.g., stage 3\u002F4 pressure ulcers, uncontrolled diabetes).\n  8. Contraindications for TSCS, such as:\n\n     8.1. Implanted Cardiac pacemaker 8.2 Implanted metal in the trunk or spinal cord 8.3 Intrathecal delivery system (e.g., baclofen pump) 8.4 Implanted central or peripheral neuromodulator\n  9. Medical condition that may put the participant at risk as determined by the investigator.\n  10. Participation in or plans to participate in another research study that may interfere with the study endpoints.","19 Years","65 Years",{"count":65,"type":22},60,"INTERVENTIONAL",[68],"NA","The investigators are looking to determine the safety and efficacy of non-invasive transcutaneous spinal cord stimulation (TSCS) in promoting recovery of lower urinary tract (LUT), bowel, sexual, and cardiovascular function, as well as spasticity in individuals with subacute and chronic SCI (time since injury 3-6 months) and the impact on quality of life. The study will be conducted at two sites; site 1 in Canada and site 2 in the Ukraine. Up to 60 subjects will be enrolled; 10 adults at the ICORD, University of British Columbia (UBC), Vancouver, Canada site and 50 adults at the Rivne Regional War Veterans Hospital, Rivne, Ukraine. Eligible participants will be randomized (1:1 ratio) either to Group 1 (G1) or Group 2 (G2). G1 will receive therapeutic TSCS for 8 weeks (3 times per week; 1 hour per session) in conjunction with conventional rehabilitation (3-4 hours per day; 5 days per week). G2 will receive 8 weeks of sham stimulation in conjunction with conventional rehabilitation. After 8 weeks, G2 will cross over and receive therapeutic TSCS for 8 weeks, whereas G1 will continue to receive TSCS therapy for another 8 weeks, for a total of 16 weeks. Eligible participants enrolled into the study will attend fifty eight (58) visits for assessments, therapy, and follow-up. The expected duration of study participation for each participant will be 33 weeks.",[71,35,72,73,74],"Spinal Cord Injuries","Sexual Dysfunction","Autonomic Dysfunction","Urologic Disorders","2026-02-23",{"date":77,"type":46},"2026-02-27",{"date":79,"type":46},"2024-10-01",{"date":81,"type":22},"2027-10-01",{"name":83,"class":53},"University of British Columbia",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":66,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":54},"100538256","enteral-feeding-of-fibre-to-improve-microbiota-100538256","NCT06288464","Enteral Feeding of Fibre to Improve Microbiota","Does Distal Enteral Feeding of Fibre Positively Affect the Microflora in the Distal Limb of Loop Ileostomy Patients?","Inclusion Criteria:\n\n* Any individual that has been identified for distal (stoma) feeding that is able to understand verbal and written English to provide informed consent.\n* Participants must be undergoing ileostomy or colostomy reversal surgery.\n\nExclusion Criteria:\n\n* Not undergoing ileostomy or colostomy reversal.\n* Persons who might not adequately understand verbal explanations or written information given in English","18 Years",{"count":93,"type":22},15,[68],"Following surgical removal of diseased bowel, patients often require a temporary redirection of bowel contents to a stoma, to allow healing prior to re-joining of the remaining bowel at a later date. Some patients may experience complications, either during or after reversal surgery, and this may be due to changes in the 'friendly' bacteria that live in our bowels. Previous research shows that the distal section of bowel that is non-functioning undergoes tissue-wasting and the 'friendly' bacteria that help our digestion die. Data shows that patients that have a reduction in their microflora are more likely to experience side effects. This study investigates a method of replenishing the microflora prior to surgery.",[35,97,98],"Colon Disease","Ileum--Diseases","2025-04-04",{"date":101,"type":46},"2025-04-06",{"date":103,"type":46},"2023-01-09",{"date":105,"type":22},"2025-12-01",{"name":107,"class":53},"Lancashire Teaching Hospitals NHS Foundation Trust",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":66,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":54},"100468520","sacral-neuromodulation-for-neurogenic-lower-urinary-tract-bowel-and-sexual-dysfunction-100468520","NCT05380856","Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction","Sacral Neuromodulation for Patients With Multiple Sclerosis With Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial.","Inclusion Criteria:\n\n* Refractory neurogenic lower urinary tract dysfunction (nLUTD) defined by visual analogue scale on treatment satisfaction ranging from 0 to 100 (100 means maximal satisfaction with the current treatment). All patients indicating satisfaction less than 50 are considered non-responders\u002Fhaving refractory overactive bladder (OAB) to current treatment\n* No effect of medical treatment defined by antimuscarinics, beta3-agonist and alpha-blocker.\n* Patients having refractory nLUTD who intend to try SNM for relief of their symptoms\n* Expanded Disability Status Scale (EDSS) \\\u003C 5 and no progression of neurological disease within 6 months\n* Written informed consent\n* Able to understand the information given about the project\n\nExclusion Criteria:\n\n* EDSS \\> 5, neurological disease with severe progression within the last 6 months and\u002For unable to manage the electronic devices\n* Age \\\u003C 18 years\n* Any other urological pathology but nLUTD\n* Bladder Pain Syndrome\u002FInterstitial cystitis\n* Any other intestinal or gynecological pathology but neurological conditional symptoms\n* Current pelvic malignancy or clinically significant pelvic mass\n* Previous pelvis radiotherapy\n* Bladder injections with botulinum neurotoxin type A within 6 months before inclusion in trial\n* Unable to manage the electronic devices\n* Inability to give an informed consent","80 Years",{"count":65,"type":22},[68],"A multi-center double-blinded placebo-controlled randomized clinical trial.\n\nThe patients will be randomized into two groups.\n\nTo investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD).\n\nAfter first step SNM-procedure and a 3-4 weeks test period patients with more than 50% improvement in the key bladder diary variables will have the IPG implanted. After a month of optimization patients will into two groups: IPG ON or IPG OFF.\n\nPeriod of randomization: four months. Number anticipated to be included: 60 patients",[120,121,122,35,72,123],"Neurogenic Dysfunction of the Urinary Bladder","Multiple Sclerosis","Sacral Neuromodulation","Quality of Life","2025-03-17",{"date":126,"type":46},"2025-03-20",{"date":128,"type":46},"2023-09-26",{"date":130,"type":22},"2027-03-01",{"name":132,"class":53},"Odense University Hospital",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100539997","impaired-toilet-training-luts-and-bowel-dysfunction-in-children-with-dcd-100539997","NCT06311110","Impaired Toilet Training, LUTS and Bowel Dysfunction in Children With DCD","Impaired Toilet Training, Lower Urinary Tract Symptoms and Bowel Dysfunction in Children With Developmental Coordination Disorder","Inclusion Criteria:\n\n* Diagnosed with DCD by a multidisciplinary team (DCD case group)\n* Children with a typical development, grade and gender matched with the DCD case group (TDC control group).\n\nExclusion Criteria:\n\n* A DCD-Q score indicative for DCD (TDC control group)\n* Presence of other developmental disorders, such as ASS, ADHD or intellectual disability (TDC control group)",true,"5 Years","8 Years",{"count":144,"type":22},84,"This cross-sectional case-control study aimed to determine whether there is a significant difference in the prevalence of impaired toilet training, LUTS, and functional bowel problems among children diagnosed with DCD and typically developing children (TDC).",[147,148,35],"Developmental Coordination Disorder","Lower Urinary Tract Symptoms","2024-08-01",{"date":151,"type":46},"2024-08-02",{"date":153,"type":46},"2023-03-14",{"date":155,"type":22},"2025-06-01",{"name":157,"class":53},"University Hospital, Ghent",2,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":66,"phases":170,"briefSummary":171,"conditions":172,"keywords":179,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":54},"100556381","effect-of-pelvic-rehabilitation-after-low-anterior-resection-for-cancer-rectum---a-randomised-controlled-trial-100556381","NCT06524362","Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial","Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial (PERECARE TRIAL)","PERECARE","Inclusion Criteria:\n\n* Age: Adults aged 18 years or older.\n* Surgical Procedure: Have undergone Low Anterior Resection (LAR) for rectal cancer.\n* Cognitive Ability: Capable of understanding and completing the questionnaires effectively\n\nExclusion Criteria:\n\n* Medical History: History of proctitis, ulcerative colitis, or Crohn's disease.\n* Surgical Extent: Extensive resection (beyond Total Mesorectal Excision - TME) for\n* locally advanced (T4) tumors, patients undergoing APR.\n* Surgical Complications: History of anastomotic leakage.\n* Recent Physiotherapy: History of invasive physiotherapy within the past 6 months.\n* Mental or Physical Inabilities: Inability to undergo Pelvic Floor Rehabilitation due to mental or physical limitations","85 Years",{"count":169,"type":22},77,[68],"Study Purpose:\n\nThis study aims to understand how pelvic floor rehabilitation (PFR) after low anterior resection (LAR) surgery for rectal cancer affects bowel control and quality of life compared to usual care.\n\nBackground:\n\nRectal cancer and its treatments can significantly impact patients' lives, often causing bowel issues like frequent bowel movements, urgency, and incontinence. These problems, known as low anterior resection syndrome (LARS), affect 70-90% of patients and can last for over two years. (1,2)\n\nCurrent Knowledge:\n\nAdvances in treatments have improved survival rates and recovery. Despite improvements, many patients still experience bowel issues after surgery.\n\nPast studies show PFR can help, but they have limitations like small sample sizes and varied methods. (3-5)\n\nNeed for the Study:\n\nThere is a need for a well-designed study to confirm the benefits of PFR and to identify which patients benefit the most.\n\nStudy Design:\n\nThis study is a randomized controlled trial that will:\n\n* Compare PFR to usual care in patients after LAR surgery.\n* Focus on bowel control and quality of life.\n* Provide detailed insights to improve aftercare for rectal cancer patients.",[173,174,175,176,177,178,35],"Rectal Cancer","Rectum Neoplasm","Rectal Neoplasms","Rectal Adenocarcinoma","Low Anterior Resection Syndrome","Fecal Incontinence",[180,181,182,183,184,185,186,187,188,189,190],"Pelvic Floor Rehabilitation","Low Anterior Resection","Ultra Low Anterior Resection","Rectal Cancer Surgery","Post operative care","Bowel function","Quality of life","Randomized controlled trial","Fecal Urgency","Pelvic Floor Muscle Training","Oncological outcomes","NOT_YET_RECRUITING","2024-07-23",{"date":194,"type":46},"2024-07-29",{"date":196,"type":22},"2024-08",{"date":198,"type":22},"2026-03",{"name":200,"class":53},"GEM Hospital & Research Center",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":208,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100431114","the-opera-study-evaluating-qol-after-rectal-cancer-surgery-100431114","NCT04893876","The OPERa Study: Evaluating QoL After Rectal Cancer Surgery","The OPERa Study: A Multicenter Observational Prospective Cohort Study to Evaluate Determinants of Long-Term Quality of Life Following Restorative Proctectomy for Rectal Cancer Treatment","Inclusion Criteria:\n\n* Patients \\>18 years with histopathologically confirmed adenocarcinoma of the rectum, defined as tumor ≤15cm from the anal verge who are planned for RP ± neoadjuvant treatment or WW (CRT alone without surgery).\n\nExclusion Criteria:\n\n* Metastatic disease at diagnosis;\n* Planned for abdominoperineal resection (APR), low Hartmann's or pelvic exenteration (PE);\n* Cannot be contacted by telephone;\n* Unable to read and comprehend English or French;\n* Unable to give clear and informed consent.",{"count":209,"type":22},1200,"Advances in rectal cancer management have significantly reduced morbidity and mortality. The most commonly performed operation for rectal cancer is restorative proctectomy (RP), leaving up to 70% with long-term bowel dysfunction called Low Anterior Resection Syndrome (LARS). LARS manifests as stool frequency, incontinence and difficult defecation. LARS, along with other functional impairments such as sexual and urinary dysfunction (SUD), can impact quality of life (QoL) and cause emotional distress. High-quality longitudinal data on these sequalae are lacking, leading to variable estimates of their prevalence, risk factors and prognosis. Most studies are European, cross-sectional, lack pre-treatment evaluation and long-term follow-up, and use inconsistent assessment measures. Thus, a North American study that evaluates patients longitudinally from diagnosis will provide quality data to fill this knowledge gap.\n\nThe main aim of the proposed study is to contribute evidence regarding the impact of LARS, SUD, emotional\u002Ffinancial distress, and patient activation on long-term post-treatment QoL in North American rectal cancer after RP.\n\nThis multicenter North American, observational, prospective cohort study relies on validated patient reported outcome measures (PROMs) at diagnosis, during and post-treatment. Patients from 20 sites will be recruited over 2 years and followed for 3 years. The primary endpoint is QoL as measured by the European Organization for Research \\& Treatment of Cancer QoL questionnaire. We anticipate accrual of 1200 patients. Factors associated with QoL will be explored. Impact of patient activation in relation to functional outcomes on QoL over time will be explored using a difference-in-differences approach. The study involves a multidisciplinary team who will provide expertise in research methodology, nursing, oncology and surgery.\n\nThe main contributions of this study are 1) provision of reference baseline North American values for important rectal cancer PROMs for clinical and research use, 2) an understanding of the evolution of functional outcomes and QoL post-treatment to counsel patients peri-operatively and throughout survivorship, and 3) to provide the basis for future tailored programs to support rectal cancer survivors.",[173,123,35,72,212,213,214],"Urinary Dysfunction","Emotional Distress","Surgery","2022-08-17",{"date":217,"type":46},"2022-08-18",{"date":219,"type":22},"2023-01-01",{"date":221,"type":22},"2029-09-30",{"name":223,"class":53},"Jewish General Hospital"]